Introduction: Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.
INTRODUCTION
Genital warts (GWs) are a sexually transmitted disease caused by human papillomavirus (HPV) and are the most common sexually transmitted disease in some countries [1, 2] . HPV6 and HPV11 are responsible for about 90% of the cases of GWs [3] . Worldwide, several million cases of GWs occur each year in both sexes, with a peak incidence between 20 and 24 years of age for females and between 25 and 29 years among males [4] .
Genital
warts usually occur about 6-12 months after the first infection with HPV [5] . However, in the placebo arms of two large randomized clinical trials assessing the quadrivalent HPV (4HPV) vaccine, the delay between PCR detection of HPV DNA and the occurrence of GWs was variable and could be as long as 2 years [3] . Data from the placebo group of these clinical trials show that GWs can spontaneously regress in up to 40% of cases [3] . Although GWs are not life-threatening, they are often associated with considerable psychosexual distress and represent an important financial and resource burden for the health system [6] . The estimates for the unit cost for a single GWs event are highly variable, depending on the type of episode (first occurrence, recurrent or persistent GWs), the management setting and type of consultation [general practice, genitourinary medicine (GUM), hospital, etc.], as well as the therapy used (medical treatment vs. surgery or other modalities) [7, 8] . A recent study in Italy reported that the most frequent cause for HPV-related hospitalization was GWs [9] . An economic analysis showed that the costs associated with GWs in men and females represented 24.3% (€70.9 million) of the total costs associated with HPV6/11/16/18 diseases in Italy. Most of the costs for 4HPV vaccination would have been covered by the prevention of GWs and the associated costs alone [10] .
Two recombinant, virus-like particle (VLP)based prophylactic HPV vaccines are currently available. One is a bivalent (2HPV) vaccine licensed for the prevention of premalignant cervical, vulvar and vaginal lesions and cervical cancer causally related to HPV16 or HPV18 in females. The other is a quadrivalent (4HPV) vaccine also licensed for the prevention of premalignant cervical, anal, vulvar and vaginal lesions and cervical and anal cancer related to HPV16 or HPV18. In addition, 4HPV is licensed for the prevention of GWs caused by HPV6 or HPV11 in both men and females [11] .
Since 2006-2007, HPV vaccines have been licensed in over 133 countries and introduced into national immunization programs in at least 40 countries [12] . Over 169 million doses of 4HPV have been distributed worldwide since its launch.
In the FUTURE I and II randomized clinical trials, 4HPV vaccine was shown to reduce the incidence of HPV6-and HPV11-related GWs in females aged between 15 and 26 years by 99% in a per-protocol susceptible population (females who were seronegative on day 1 and DNA negative on day 1 through month 7 to the respective HPV type, who received three doses of vaccine) [13] . A reduction of 62% was reported in an intent-to-treat population (females with past or current HPV exposure and those naïve to HPV who received[1 dose of vaccine) [13] .
In countries that have implemented national vaccination programs against HPV, health economics models have estimated that the impact of these programs will only be seen for cervical cancer and other HPV-related cancers, at the population level, 30-50 years after the initiation of the vaccination program, due to the generally long time lag between infection and cancer [14, 15] . However, since HPV-related GWs develop rapidly after HPV infection, with a peak incidence between 20 and 35 years of age, the vaccine impact on their incidence should be visible earlier.
It is important to survey the impact of any new vaccine. Although some registries and surveillance systems have been set up to monitor the impact of 4HPV vaccination on cervical cancer and other HPV-related diseases, they are heterogeneous and not implemented everywhere. In addition, these diseases, which take a certain time to develop, will only occur a long time after vaccine programs have been implemented. Since the impact of HPV vaccination on GWs will be seen earlier, the surveillance of their incidence and prevalence is a good indicator of the impact of vaccination on other vaccine-related HPV diseases and cancers. Data on the incidence and prevalence of GWs will not be available for all countries, as
GWs are not a notifiable disease everywhere. However, some data can be obtained through sentinel surveillance systems for sexually transmitted infections or through the implementation of national networks using a sample of first-level 'sentinel' general practitioners or gynecologists, as has been done in Italy [16, 17] . Nevertheless, assessing the impact of HPV vaccination in a reliable and robust manner is easier in countries that have good surveillance systems for GW, e.g. United Kingdom (UK), Australia, and the Nordic countries.
The aim of the present review article is to summarize the published data reporting the early impact of HPV vaccination on GWs in countries that have introduced 4HPV into their national immunization programs. We specifically looked at countries where the 4HPV vaccine is recommended, either exclusively or not, since this is the only available vaccine licensed for the prevention of GWs via HPV6 and HPV11
included in the vaccine [11] . Table 1) . Some of the studies also reported that the incidence of GWs in men who have sex with men (MSM) was stable during the studied period [18, 20, 21] . Two studies reported that the incidence of other sexually transmitted diseases, chlamydia and genital herpes, increased or remained stable over studied period [18, 27] .
METHODS
In this review, we present data for the direct impact/effectiveness in vaccinated cohorts. We also present data for the indirect impact, or herd protection, in the unvaccinated population, since this contributes to the overall impact of the vaccine. The unvaccinated population has been divided further:
• Heterosexual men of a similar age who could have sex with vaccinated females and therefore could be expected to benefit from herd protection;
• Older females who are less likely to be vaccinated and older heterosexual men who are less likely to benefit from herd protection;
• MSM who are unlikely to have sex with vaccinated females, and at the time of the studies, male vaccination had not been recommended.
Due to the diversity of the study designs, the HPV vaccination programs and vaccine uptake rates, the results are presented country by country.
Australia
Australia was one of the first countries to implement a fully funded national populationbased 4HPV vaccination program in April 2007. and another that analyzed national hospital data for GWs [22, 23] .
In the first report from Melbourne, the years analyzed were from January 2004 to December 2008 whereas in the later report they were from July 2004 to June 2011 [20, 21] . In addition, the subgroups analyzed were different. Despite these differences, rapid and significant declines with GWs, in the same period [19] . No significant reductions were seen for nonresident females of eligible age, females and heterosexual men aged[26 years or MSM. The second report from this study, reporting data for up to 4 years after 4HPV vaccine introduction, showed a further decrease up to 92.6% in the percentage of females aged\21 years with GWs, from 11.5% in 2007 to 0.85% (i.e., 13 cases) in 2011 [18] . None of the 235 females aged\21 years who had been vaccinated were diagnosed with GWs. In females aged confirmed the decline in GWs and the increase in chlamydia infections [23] . The analysis of Australian national hospital data between 1999 and 2011 confirmed the reduction of GWs in young females and also in young men (herd protection), with a similar impact in indigenous and non-indigenous populations [22] .
New Zealand
The 4HPV vaccine was introduced in New (Table 1 ) [24] . A similar, but statistically non-significant, reduction was observed in young males.
Another study used a prescription database (PHARMAC) to assess the impact on prescriptions for GW treatments (imiquimod and podophyllum) and as a surrogate outcome for GWs [25] . They reported the largest decrease in prescriptions in females aged under 20 years (Table 1) .
United States
The 4HPV vaccine was introduced in the United States (US) in June 2006 for females aged 11-12 years with catch-up for those aged 13-26 years; in 2011, the recommendations were extended to males aged 11-12 years with catch-up for those aged 13-21 years [35, 36] . The uptake rate for C1 dose among adolescents aged 13-17 years in 2010 varied from 22.5% in the US Virgin Islands to 73.0% in Rhode Island with a national average of 48.7% [37] . In females and males aged 19-26 years, the uptake was 20.7% and 0.6%, respectively [38] .
Three studies reported data showing the impact of 4HPV vaccination on GWs [26] [27] [28] .
One study included 64 million person-years of data for subjects aged 10-39 years enrolled in about 100 health insurance plans throughout the US [27] . The results showed a significant decline in the prevalence of GWs 4 years after the introduction of 4HPV vaccination There was no evidence of a reduction in incidence in older females and males.
Sweden
From May 2007, 4HPV vaccine has been available at a subsidized cost for females aged 13-17 years; vaccination was, therefore, administered in clinics and costs were incurred by the females or their parents. It was estimated that 25% of females aged 13-20 years had received C1 dose of 4HPV [32] . Vaccine uptake rates were highest in those aged 18-19 years (31.9%) and those aged 13-17 years (24.7%) [33] .
Two studies reported results from the analysis of data extracted from the Swedish Prescribed Drug and the National Patient
Registers to identify GW episodes in the population aged between 10 and 44 years between 2006 and 2010 [32, 33] . One of the studies showed significant decreases in the incidence of GWs in females aged 15-25 years from 2006 to 2010 (P\0.001 test for trend); the decrease was highest ([25%) in those aged 17 and 18, with significant decreases up to 25 years [32] . No significant trends over time were observed for males (P = 0.71 test for trend).
The second study reported a vaccine effectiveness of 76% (95% CI 73-79%) among females who received three doses of vaccine with the first dose before 20 years [33] . The effectiveness was highest in those vaccinated before 14 years (93%) compared with 71% between 17-and 19-year old and 48% between 20-and 22-year old.
DISCUSSION
This summary of published data provides evidence that there is a rapid reduction in the incidence of GWs after the implementation of 4HPV vaccination, at least, in the target population, despite the differences in study designs, populations studied, and 4HPV vaccine implementation and uptake. The results for the trends of other sexually transmitted diseases that increased or remained stable suggest that the reduction in GW incidence is unlikely to be explained by changes in sexual health education or in sexual behavior [18, 29] .
Results from the study in Sweden suggest that vaccination at an early age results in higher protection, with the highest effectiveness for vaccination at 10-13 years [33] . The younger the subjects are at vaccination, the less likely they are to have been in contact with HPV, and therefore, the more likely they will be protected with a prophylactic vaccine such as 4HPV vaccine.
The results from this review also provide some evidence for possible herd protection in unvaccinated populations of men and older females, particularly in settings with high vaccine uptake rates [18] . However, herd protection was not seen in all countries (e.g., Denmark) suggesting that factors other than vaccination, for example, population dynamics could contribute to herd protection [29] . A study in Australia using a national general practice database, published after our literature search had been done, reported a reduction of 61% in GW management rate in vaccineeligible females for the post-vaccination period (July 2008-June 2012) but no change in older females or in males of any age [39] .The US Centers for Disease Control and Prevention reported that male HPV infections are responsible for about one-third of the total expected burden of HPV-associated cancers, emphasizing how universal vaccination could be beneficial by providing direct protection [40] . Certain populations, such as MSM, will not benefit from herd protection from a female HPV vaccine program. Thus, it is reasonable to consider universal HPV vaccination programs to provide direct protection to all individuals, irrespective of their gender [41] . Despite the considerable indirect effects seen in Australia, the Australian government has implemented a publically funded program for 4HPV vaccination in boys aged 12-13 years, with a 2-year catch-up program for boys aged 14-15 years [42] . In early 2014, Austria started a vaccination program for both boys and females [43, 44] . In the UK, the Joint Committee on Vaccination and Immunization is considering extending the HPV vaccination program; a group of parliamentarians with a special interest in public health published an open letter in support of extending to the program to males [45] .
Although the 2HPV vaccine does not contain HPV6 or HPV11, an unexpected result was reported from an ecological study in the UK.
2HPV vaccination was introduced in September 2008 for females aged 12-13 years with catch-up for those up to 18-year old. The vaccine uptake was reported to be[80% in the routine cohorts and about 40% or more in the oldest catch-up cohorts [46] . It was reported that there were reductions in diagnoses of GW in GUM clinics of 13.3% in females aged [16] [17] [18] [19] showed that while HPV6/11 were present in 86.0% (447/520) of the GWs analyzed in which HPV was detected, HPV16/18 were also present in 13.4% (64/478) of these lesion [3] .
In September 2012, the UK switched to the 4HPV vaccine in their program. Due to direct protection against HPV 6 and 11 conferred by 4HPV, greater reductions in the incidence of GWs are expected to be observed; and this will also accompanied by reductions in HPV6 and HPV11 infections. In the US, 4 years after 4HPV vaccine introduction, in females aged 14-19 years, a decline of 56% (11.5-5.1%) of vaccine-type HPV infection was reported despite a low vaccine uptake rate; vaccine effectiveness for C1 dose was estimated to be 82% [51] . In Germany, where the vaccine uptake is also low, a similar decline of 54.5% (22.4-10.2%) in HPV16/18 infections has been reported in females aged 20-21 years [52] .
Recently in Belgium, the results from a retrospective study between September 2009
and January 2012 in females aged 15-19 and 20-24 years showed a significant decrease in HPV 16 infection in the younger age group, with a similar-sized reduction for HPV18, which was not significant [53] . In the older age group,
where HPV vaccination uptake is lower, the incidence remained stable over the period, suggesting that the observed decrease is due to HPV vaccination. While the first indication of the clinical impact of HPV vaccination has been shown by the reduction in the incidence of GWs, the impact on the incidence of cervical abnormalities that can give rise to precancerous and cancerous cervical lesions is suggestive of a long-term clinical impact. Recent data, including two reviews, showing a significant reduction in the incidence of cervical abnormalities in countries where 4HPV was introduced early and with high vaccine uptake have been published [54] [55] [56] [57] [58] [59] .
The studies presented in this review are either analysis of national or very large regional databases. Some of the studies reported the vaccination status of the subjects and so provided effectiveness data. Although some of the studies included present the classical potential limitations of databasebased and ecological studies, including erroneous coding, underreporting to the databases and potential biases, they allow a pragmatic approach to continual assessment of national vaccination programs. Another possible limitation that should be acknowledged is the potential publication bias, which is inherent to literature reviews. However, the authors feel, that as this is an area of high interest, the studies are reported. After the end of the literature search and the submission of the paper we identified an additional study that was not included in the formal review but presented in the discussion.
Since GWs are not notifiable diseases in all countries, dedicated surveillance programs have not been implemented as they have been for some diseases, such as invasive pneumococcal diseases and influenza [60] .
Despite their limitations, these results show that 4HPV vaccination programs have the potential to significantly reduce the burden associated with GWs. Some models, based on data from clinical trials and estimates for the high burden of GWs to healthcare systems, predict that vaccination costs can be offset by reductions in GW disease costs [10] . The studies in this overview can be used to verify the reliability of published models on the timing of reduction of such diseases and the possible impact of vaccination programs in countries with no surveillance systems. In summary, the data from these international studies (6 countries, 3 different continents) summarized in this review give an encouraging view of the early clinical impact of introducing 4HPV into national vaccination programs. 
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